185 related articles for article (PubMed ID: 36692401)
1. Multicenter Validation of Abbreviated MRI for Detecting Early-Stage Hepatocellular Carcinoma.
Yokoo T; Masaki N; Parikh ND; Lane BF; Feng Z; Mendiratta-Lala M; Lee CH; Khatri G; Marsh TL; Shetty K; Dunn CT; Al-Jarrah T; Aslam A; Davenport MS; Gopal P; Rich NE; Lok AS; Singal AG
Radiology; 2023 Apr; 307(2):e220917. PubMed ID: 36692401
[TBL] [Abstract][Full Text] [Related]
2. Gadoxetate-enhanced Abbreviated MRI for Hepatocellular Carcinoma Surveillance: Preliminary Experience.
Brunsing RL; Chen DH; Schlein A; Wolfson T; Gamst A; Mamidipalli A; Vietti Violi N; Marks RM; Taouli B; Loomba R; Kono Y; Sirlin CB
Radiol Imaging Cancer; 2019 Nov; 1(2):e190010. PubMed ID: 33778680
[TBL] [Abstract][Full Text] [Related]
3. Abbreviated-protocol screening MRI vs. complete-protocol diagnostic MRI for detection of hepatocellular carcinoma in patients with cirrhosis: An equivalence study using LI-RADS v2018.
Khatri G; Pedrosa I; Ananthakrishnan L; de Leon AD; Fetzer DT; Leyendecker J; Singal AG; Xi Y; Yopp A; Yokoo T
J Magn Reson Imaging; 2020 Feb; 51(2):415-425. PubMed ID: 31209978
[TBL] [Abstract][Full Text] [Related]
4. Can the patient with cirrhosis be imaged for hepatocellular carcinoma without gadolinium?: Comparison of combined T2-weighted, T2*-weighted, and diffusion-weighted MRI with gadolinium-enhanced MRI using liver explantation standard.
Hardie AD; Kizziah MK; Rissing MS
J Comput Assist Tomogr; 2011; 35(6):711-5. PubMed ID: 22082541
[TBL] [Abstract][Full Text] [Related]
5. Gadoxetate-enhanced abbreviated MRI is highly accurate for hepatocellular carcinoma screening.
Vietti Violi N; Lewis S; Liao J; Hulkower M; Hernandez-Meza G; Smith K; Babb JS; Chin X; Song J; Said D; Kihira S; Sirlin CB; Reeder SB; Bashir MR; Fowler KJ; Ferket BS; Sigel K; Taouli B
Eur Radiol; 2020 Nov; 30(11):6003-6013. PubMed ID: 32588209
[TBL] [Abstract][Full Text] [Related]
6. Detection of hepatocellular carcinoma in gadoxetic acid-enhanced MRI and diffusion-weighted MRI with respect to the severity of liver cirrhosis.
Kim AY; Kim YK; Lee MW; Park MJ; Hwang J; Lee MH; Lee JW
Acta Radiol; 2012 Oct; 53(8):830-8. PubMed ID: 22847903
[TBL] [Abstract][Full Text] [Related]
7. The combination of non-contrast abbreviated MRI and alpha foetoprotein has high performance for hepatocellular carcinoma screening.
Girardet R; Dubois M; Manasseh G; Jreige M; Du Pasquier C; Canniff E; Gulizia M; Bonvin M; Aleman Y; Taouli B; Fraga M; Dromain C; Vietti Violi N
Eur Radiol; 2023 Oct; 33(10):6929-6938. PubMed ID: 37464111
[TBL] [Abstract][Full Text] [Related]
8. Abbreviated MRI for Secondary Surveillance of Recurrent Hepatocellular Carcinoma After Presumed Curative Treatment.
Jeon SK; Lee DH; Hur BY; Park SJ; Kim SW; Park J; Suh KS; Lee KW; Yi NJ; Han JK
J Magn Reson Imaging; 2023 Nov; 58(5):1375-1383. PubMed ID: 36825827
[TBL] [Abstract][Full Text] [Related]
9. Comparison of diagnostic performance of non-contrast MRI and abbreviated MRI using gadoxetic acid in initially diagnosed hepatocellular carcinoma patients: a simulation study of surveillance for hepatocellular carcinomas.
Whang S; Choi MH; Choi JI; Youn SY; Kim DH; Rha SE
Eur Radiol; 2020 Aug; 30(8):4150-4163. PubMed ID: 32166493
[TBL] [Abstract][Full Text] [Related]
10. LI-RADS Version 2017 versus Version 2018: Diagnosis of Hepatocellular Carcinoma on Gadoxetate Disodium-enhanced MRI.
Lee SM; Lee JM; Ahn SJ; Kang HJ; Yang HK; Yoon JH
Radiology; 2019 Sep; 292(3):655-663. PubMed ID: 31310175
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic performance of gadoxetic acid-enhanced abbreviated magnetic resonance imaging protocol in small hepatocellular carcinoma (≤2 cm) in high-risk patients.
Wang JH; Qiu QS; Dong SY; Chen XS; Wang WT; Yang YT; Sun W; Rao SX
Acta Radiol; 2023 Oct; 64(10):2687-2696. PubMed ID: 37691270
[TBL] [Abstract][Full Text] [Related]
12. Radiologic-Pathologic Correlation of Hepatobiliary Phase Hypointense Nodules without Arterial Phase Hyperenhancement at Gadoxetic Acid-enhanced MRI: A Multicenter Study.
Joo I; Kim SY; Kang TW; Kim YK; Park BJ; Lee YJ; Choi JI; Lee CH; Park HS; Lee K; Kim H; Yu E; Kang HJ; Ha SY; Kim JY; Ahn S; Jung ES; Kim BH; Han HS; Lee JM
Radiology; 2020 Aug; 296(2):335-345. PubMed ID: 32484414
[TBL] [Abstract][Full Text] [Related]
13. Value of gadoxetic acid-enhanced MRI and diffusion-weighted imaging in the differentiation of hypervascular hyperplastic nodule from small (<3 cm) hypervascular hepatocellular carcinoma in patients with alcoholic liver cirrhosis: A retrospective case-control study.
Kim SS; Kim SH; Song KD; Choi SY; Heo NH
J Magn Reson Imaging; 2020 Jan; 51(1):70-80. PubMed ID: 31062483
[TBL] [Abstract][Full Text] [Related]
14. Prospective evaluation of Gadoxetate-enhanced magnetic resonance imaging and computed tomography for hepatocellular carcinoma detection and transplant eligibility assessment with explant histopathology correlation.
Jhaveri KS; Babaei Jandaghi A; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G
Cancer Imaging; 2023 Feb; 23(1):22. PubMed ID: 36841796
[TBL] [Abstract][Full Text] [Related]
15. Comparison of international guidelines for diagnosis of hepatocellular carcinoma and implications for transplant allocation in liver transplantation candidates with gadoxetic acid enhanced liver MRI versus contrast enhanced CT: a prospective study with liver explant histopathological correlation.
Odedra D; Jandaghi AB; Bhayana R; Elbanna KY; Espin-Garcia O; Fischer SE; Ghanekar A; Sapisochin G; Jhaveri KS
Cancer Imaging; 2022 Oct; 22(1):55. PubMed ID: 36195953
[TBL] [Abstract][Full Text] [Related]
16. Abbreviated MRI for Hepatocellular Carcinoma Screening and Surveillance.
An JY; Peña MA; Cunha GM; Booker MT; Taouli B; Yokoo T; Sirlin CB; Fowler KJ
Radiographics; 2020; 40(7):1916-1931. PubMed ID: 33136476
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
[TBL] [Abstract][Full Text] [Related]
18. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the diagnosis of early recurrence of hepatocellular carcinoma.
Rimola J; Forner A; Sapena V; Llarch N; Darnell A; Díaz A; García-Criado A; Bianchi L; Vilana R; Díaz-González Á; Ayuso C; Bruix J; Reig M
Eur Radiol; 2020 Jan; 30(1):186-194. PubMed ID: 31372783
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Gadobenate-Enhanced MRI and Gadoxetate-Enhanced MRI for Hepatocellular Carcinoma Detection Using LI-RADS Version 2018: A Prospective Intraindividual Randomized Study.
Rong D; He B; Tang W; Xie S; Kuang S; Grazioli L; Hussain SM; Yang Y; Wang J
AJR Am J Roentgenol; 2022 Apr; 218(4):687-698. PubMed ID: 34817191
[No Abstract] [Full Text] [Related]
20. Diagnostic Performance of LI-RADS Treatment Response Algorithm for Hepatocellular Carcinoma: Adding Ancillary Features to MRI Compared with Enhancement Patterns at CT and MRI.
Park S; Joo I; Lee DH; Bae JS; Yoo J; Kim SW; Lee JM
Radiology; 2020 Sep; 296(3):554-561. PubMed ID: 32692297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
